Want to see TRDA full AI Analyst Report?
Top Page
Entrada Therapeutics Inc
(NASDAQ:TRDA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.00
▲(19.66% Upside)
Action:Reiterated
Date:08/05/26
TRDA’s score is held down primarily by weak financial performance (large TTM losses and substantial cash burn) despite a relatively conservative balance sheet. Technicals are mixed—near-term trading is firmer but longer-term trend remains below key averages. Corporate events are a positive offset due to encouraging clinical data and stated funding runway into Q3 2027, while valuation is constrained by negative earnings and no indicated dividend support.
Positive Factors
Solid balance sheet and runway
Entradas's cash position (~$254.9M) and sizable assets provide a multi-quarter runway (stated funding into Q3 2027). This durable liquidity buffer reduces near-term refinancing pressure, allowing focus on clinical execution and multiple readouts without immediate reliance on dilutive capital.
Negative Factors
High cash burn and negative cash flow
Sustained operating and free cash outflows near ~$134M TTM reflect an intensive R&D spending profile. Over a multi-quarter horizon this burn rate raises refinancing risk and forces management to prioritize programs, potentially delaying or compressing development plans if additional non-dilutive funding is unavailable.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid balance sheet and runway
Entradas's cash position (~$254.9M) and sizable assets provide a multi-quarter runway (stated funding into Q3 2027). This durable liquidity buffer reduces near-term refinancing pressure, allowing focus on clinical execution and multiple readouts without immediate reliance on dilutive capital.
Read all positive factors
Entrada Therapeutics Inc (TRDA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$263.59M
Dividend YieldN/A
Average Volume (3M)378.31K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth-96.67%
EPS Growth-559.52%
CountryUS
Employees152
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.97
Shares Outstanding38,820,618
10 Day Avg. Volume453,749
30 Day Avg. Volume378,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.67Price Target Upside184.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.91
Revenue Forecast (FY)$19.37M
Entrada Therapeutics Inc Business Overview & Revenue Model
Company Description
Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biotechnology company focused on developing therapies for diseases that require delivering biologic drugs into cells. The company’s core technology platform, referred to publicly as Endosomal E...
How the Company Makes Money
TRDA is a clinical-stage biotechnology company and does not primarily generate revenue from product sales because it does not have approved commercial products. Instead, its revenue, when present, is generally derived from collaboration and licens...
Entrada Therapeutics Inc Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.69M | 25.42M | 210.78M | 129.01M | 0.00 | 0.00 |
| Gross Profit | -35.37M | 21.32M | 210.78M | 129.01M | 0.00 | 0.00 |
| EBITDA | -164.87M | -142.40M | 70.26M | 14.90M | -90.09M | -50.04M |
| Net Income | -165.78M | -143.75M | 65.63M | -6.68M | -94.62M | -51.16M |
Balance Sheet | ||||||
| Total Assets | 298.88M | 377.38M | 526.32M | 469.19M | 252.06M | 305.83M |
| Cash, Cash Equivalents and Short-Term Investments | 223.00M | 295.70M | 420.00M | 351.97M | 188.71M | 291.06M |
| Total Debt | 48.54M | 50.93M | 59.21M | 68.23M | 25.94M | 0.00 |
| Total Liabilities | 65.47M | 71.25M | 97.64M | 226.83M | 39.50M | 7.12M |
| Stockholders Equity | 233.41M | 306.13M | 428.68M | 242.36M | 212.55M | 298.72M |
Cash Flow | ||||||
| Free Cash Flow | -134.35M | -129.55M | -44.72M | 134.19M | -96.67M | -55.44M |
| Operating Cash Flow | -134.67M | -128.51M | -41.56M | 139.80M | -93.79M | -50.86M |
| Investing Cash Flow | 160.16M | 116.81M | -27.80M | -138.40M | -148.65M | -4.58M |
| Financing Cash Flow | 650.00K | 887.00K | 102.96M | 21.04M | 479.00K | 307.46M |
Entrada Therapeutics Inc Technical Analysis
Neutral
5.85
Price Trends
6.83
Positive
9.16
Negative
9.66
Negative
Market Momentum
-0.04
Negative
50.49
Neutral
59.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Neutral. The current price of 5.85 is below the 20-day moving average (MA) of 6.62, below the 50-day MA of 6.83, and below the 200-day MA of 9.66, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 50.49 is Neutral, neither overbought nor oversold. The STOCH value of 59.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TRDA.
Entrada Therapeutics Inc Risk Analysis
Entrada Therapeutics Inc disclosed 93 risk factors in its most recent earnings report. Entrada Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Entrada Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $384.77M | -2.92 | -50.68% | ― | -12.37% | 19.59% | |
54 Neutral | $435.02M | -5.27 | -37.57% | ― | ― | 24.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $263.59M | -1.70 | -57.61% | ― | -96.67% | -559.52% | |
48 Neutral | $96.84M | -2.22 | -38.80% | ― | -100.00% | -1056.82% |
* Healthcare Sector Average
TRDA
Entrada Therapeutics Inc
6.87
1.57
29.62%
BDTX
Black Diamond Therapeutics
1.92
-0.36
-15.79%
CCCC
C4 Therapeutics
3.64
1.06
41.09%
SGMT
Sagimet Biosciences, Inc. Class A
8.74
-0.31
-3.43%
Entrada Therapeutics Inc Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
Positive
Jun 10, 2026
Entrada Therapeutics Inc. held its Annual Meeting of stockholders on June 10, 2026, with 33,190,234 of 38,820,616 eligible common shares represented, establishing a quorum for all matters up for vote. Stockholders elected Peter S. Kim, Ph.D., and ...
Business Operations and StrategyRegulatory Filings and Compliance
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
Positive
May 19, 2026
On May 18, 2026, Entrada Therapeutics updated its corporate presentation to highlight what it calls a transformational year, underscored by five clinical-stage programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 and a deepening p...
Business Operations and StrategyFinancial Disclosures
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
Positive
May 7, 2026
On May 7, 2026, Entrada Therapeutics reported first-quarter 2026 results and unveiled positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-44-201 trial of ENTR-601-44 in boys with Duchenne muscular dystrophy amenable to exon 44 skipping. P...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.